...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Debt

But the 64 thousand dollar question is, how and why is the top 70% of shareholders still give him their full support by leaving him the top boss of RVX. They can very easily vote him out altogether. Hard to explain.

 

Koo

Share
New Message
Please login to post a reply